MedComm

Scope & Guideline

Unleashing Potential in Drug Discovery and Genetics

Introduction

Welcome to your portal for understanding MedComm, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherWILEY
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationMEDCOMM / MedComm
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

MedComm focuses on advancing the understanding of human health and disease through innovative research methodologies, with a strong emphasis on molecular mechanisms, therapeutic strategies, and translational applications.
  1. Molecular Mechanisms of Disease:
    The journal emphasizes the exploration of molecular pathways involved in various diseases, including cancer, metabolic disorders, and autoimmune diseases, providing insights into their pathogenesis and potential therapeutic targets.
  2. Therapeutic Innovations:
    MedComm publishes studies on novel therapeutic strategies, including drug development, immunotherapy, and gene editing technologies, aimed at addressing unmet medical needs across a range of diseases.
  3. Translational Research:
    The journal highlights research that bridges the gap between laboratory findings and clinical applications, focusing on how basic science can inform clinical practice and improve patient outcomes.
  4. Emerging Technologies in Medicine:
    MedComm is at the forefront of publishing research related to cutting-edge technologies such as CRISPR, nanomedicine, and bioprinting, which are transforming the landscape of biomedical research and treatment.
  5. Interdisciplinary Approaches:
    The journal encourages interdisciplinary research that integrates fields such as genomics, proteomics, microbiome studies, and bioinformatics to provide comprehensive insights into health and disease.
Recent trends in MedComm's publications indicate a dynamic shift towards innovative research areas that reflect the evolving landscape of biomedical science.
  1. Cancer Immunotherapy:
    There is a significant increase in research related to cancer immunotherapy, including novel approaches like CAR-T cell therapy and immune checkpoint inhibitors, highlighting the importance of harnessing the immune system in cancer treatment.
  2. Precision Medicine and Genomics:
    The journal has seen a surge in publications focused on precision medicine, including genomic profiling and personalized treatment strategies, reflecting a growing emphasis on tailored healthcare solutions.
  3. Microbiome Research:
    Emerging studies investigating the role of the microbiome in health and disease are gaining traction, showcasing the interconnectedness of gut health and various systemic diseases.
  4. Regenerative Medicine:
    Research into regenerative medicine, including stem cell therapy and tissue engineering, is on the rise, emphasizing the potential for repairing or replacing damaged tissues and organs.
  5. Neuroinflammation and Neurodegenerative Diseases:
    An increasing focus on the mechanisms of neuroinflammation and its role in neurodegenerative diseases reflects a broader interest in understanding brain health and potential therapeutic targets.

Declining or Waning

While MedComm continues to expand its research horizons, certain themes have shown a decline in prominence or frequency of publication, reflecting shifting priorities within the field.
  1. Traditional Pharmaceutical Approaches:
    There has been a noticeable decrease in studies focusing solely on traditional pharmaceutical interventions, as the field shifts towards more innovative and personalized therapeutic strategies.
  2. Basic Descriptive Studies:
    The journal has seen fewer publications of basic descriptive studies that do not offer substantial insights into mechanisms or therapeutic implications, indicating a move towards more hypothesis-driven research.
  3. Single-Disease Focus:
    Research focusing exclusively on single diseases without considering comorbidities or broader health implications is becoming less common, as interdisciplinary approaches gain traction.
  4. Clinical Trials Reporting:
    The frequency of clinical trial reports has diminished, possibly due to the journal's emphasis on mechanistic and translational research over straightforward clinical outcomes.

Similar Journals

Genes & Diseases

Bridging the gap between genetics and clinical applications.
Publisher: KEAI PUBLISHING LTDISSN: 2352-4820Frequency: 6 issues/year

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

Current Molecular Pharmacology

Advancing the Frontiers of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

Frontiers in Molecular Biosciences

Fostering Collaboration in Cutting-Edge Molecular Research
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Frontiers in Molecular Biosciences is an esteemed open-access journal published by FRONTIERS MEDIA SA, based in Switzerland. Since its inception in 2014, the journal has made significant strides in the fields of biochemistry, genetics, and molecular biology, cementing its reputation with a solid position in the Q1 quartile for both Biochemistry and Genetics and Molecular Biology (miscellaneous) categories as of 2023. With a remarkable Scopus rank of #14/103 in the combined categories, it offers an essential platform for the dissemination of high-quality research that shapes the understanding of molecular processes and their implications in health and disease. The journal’s commitment to open access facilitates the broadest possible reach for groundbreaking discoveries, serving as a vital resource for researchers, professionals, and students alike. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, this journal continues to foster innovative discussions and advancements in molecular biosciences, paving the way for new insights and collaborations in the scientific community.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pioneering Insights in Cell Biology and Molecular Medicine
Publisher: WILEYISSN: 1582-1838Frequency: 12 issues/year

Journal of Cellular and Molecular Medicine, published by Wiley, stands at the forefront of research excellence in the fields of cell biology and molecular medicine. With an impressive impact factor reflected in its 2023 Q2 category ranking for both Cell Biology and Molecular Medicine, this journal provides a vital platform for researchers and professionals alike, fostering innovative findings and groundbreaking discoveries since its inception in 2000. Maintaining an open access policy since 2012, the journal ensures that knowledge is freely disseminated, promoting collaboration and progress across the scientific community. With robust rankings in the Scopus database, including a position within the top 85th percentile in Molecular Medicine, the journal remains committed to advancing understanding of cellular functions and their implications in health and disease. Researchers, professionals, and students will find a treasure of high-quality articles and reviews that not only catalyze academic dialogue but also contribute significantly to practical applications in the life sciences.

CURRENT OPINION IN PHARMACOLOGY

Illuminating Trends in Pharmacology and Beyond
Publisher: ELSEVIER SCI LTDISSN: 1471-4892Frequency: 6 issues/year

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

Discovery Medicine

Transforming insights into impactful medical discoveries.
Publisher: DISCOVERY MEDICINEISSN: 1539-6509Frequency: 6 issues/year

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

MOLECULAR CANCER RESEARCH

Innovating Cancer Research for Tomorrow's Therapies
Publisher: AMER ASSOC CANCER RESEARCHISSN: 1541-7786Frequency: 12 issues/year

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

Cell Reports Medicine

Unlocking the potential of medicine through open access research.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

EXPERIMENTAL AND MOLECULAR PATHOLOGY

Leading the way in molecular pathology research.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0014-4800Frequency: 6 issues/year

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

BioImpacts

Catalyzing innovative research for a healthier future.
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5652Frequency: 4 issues/year

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.